by Symmetron | Jan 19, 2019
Cancer Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom Value in Health. 2017; 20(9):A427 Authors Bermingham S, Schmid P, Forster F, Cornic L, Theti D, Smith A Noteworthy This is the first study to...
by Symmetron | Jan 17, 2019
Medically unexplained symptoms The cost of somatisation among the working-age population in England for the year 2008–2009 Mental Health in Family Medicine. 2010;7:71–84 Awards Any awards or notable things to say about this? Process \ A \ B \ C...
by Symmetron | Jan 17, 2019
Idiopathic Pulmonary Fibrosis A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK PharmacoEconomics. 2017 Apr;35(4):479-491 Authors Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A Process \ An...
by Symmetron | Jan 17, 2019
Idiopathic Pulmonary Fibrosis The burden of illness of idiopathic pulmonary fibrosis:a comprehensive evidence review PharmacoEconomics. 2018;36:779–807 Awards Top PharmacoEconomics article of 2018! Downloads and counting Authors Diamantopoulos A, Wright E,...
Recent Comments